5 hours Ago By ABMN Staff
Adaptive Biotechnologies ( NASDAQ:ADPT – Free Report ) had its price objective boosted by BTIG Research from $8.00 to $9.00 in a research note issued to investors on Wednesday morning, Benzinga reports.
BTIG Research currently has a buy rating on the stock. Separately, Piper Sandler boosted their price target on Adaptive Biotechnologies from $6.00 to $7.
00 and gave the company an “overweight” rating in a research note on Monday, November 11th. View Our Latest Research Report on ADPT Adaptive Biotechnologies Stock Up 6.5 % Institutional Investors Weigh In On Adaptive Biotechnologies Several institutional investors and hedge funds have recently added to or reduced their stakes in ADPT.
The Manufacturers Life Insurance Company boosted its stake in shares of Adaptive Biotechnologies by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 48,834 shares of the company’s stock worth $177,000 after acquiring an additional 2,710 shares during the last quarter.
Vontobel Holding Ltd. lifted its holdings in shares of Adaptive Biotechnologies by 30.8% in the 3rd quarter.
Vontobel Holding Ltd. now owns 17,000 shares of the company’s stock worth $87,000 after acquiring an additional 4,000 shares during the last quarter. JTC Employer Solutions Trustee Ltd purchased a new position in shares of Adaptive Biotechnologies during the third quarter worth $26,000.
IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Adaptive Biotechnologies by 29.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,576 shares of the company’s stock valued at $131,000 after acquiring an additional 5,826 shares during the period.
Finally, B. Riley Wealth Advisors Inc. grew its holdings in shares of Adaptive Biotechnologies by 48.
1% in the third quarter. B. Riley Wealth Advisors Inc.
now owns 20,000 shares of the company’s stock valued at $102,000 after purchasing an additional 6,500 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.
About Adaptive Biotechnologies ( Get Free Report ) Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. Read More Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.
com's FREE daily email newsletter ..
